What if Pharma 'voluntary' direct-to-patient pricing blunts MFN threat?
Lilly and Pfizer launch cash direct-to-consumer pricing to pre-empt MFN, partially defusing the political risk and prompting a relief rally in the drug names.
Every number ships with its receipt — the odds, the range, the precedents, and a public grade at Reality Check. The statistical machinery that produces it is proprietary.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (electric blue) over time vs the market's (Polymarket, amber), from the past toward the 6–18 months horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. Loading the probability audit trail…
What it would mean
If this plays out, it is a risk-on shock. Lilly and Pfizer launch cash direct-to-consumer pricing to pre-empt MFN, partially defusing the political risk and prompting a relief rally in the drug names. The trigger decomposes into signed root‑shocks — Biotech breakthrough ▲ · Consumer spending ▲ · Risk appetite ▲ — which propagate through our causal graph to the markets below.